The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
06
11
2022
accepted:
10
03
2023
revised:
05
02
2023
medline:
9
6
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.
Identifiants
pubmed: 36977926
doi: 10.1038/s41409-023-01955-z
pii: 10.1038/s41409-023-01955-z
pmc: PMC10044103
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-624Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, et al. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia—A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. Clin Lymphoma Myeloma Leuk. 2017;17:667–5.e2.
doi: 10.1016/j.clml.2017.06.007
pubmed: 28694085
Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130:1477–80.
doi: 10.1182/blood-2017-04-775841
pubmed: 28716861
Tournilhac O, Garff-Tavernier ML, Quoc SN, Forcade E, Chevallier P, Legrand-Izadifar F, et al. Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial. Haematologica. 2021;106:1867–75.
doi: 10.3324/haematol.2019.239566
pubmed: 32527951
Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Pract Res Clin Haematol. 2016;29:54–66.
doi: 10.1016/j.beha.2016.08.001
pubmed: 27742072
Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96:1679–705.
doi: 10.1002/ajh.26367
pubmed: 34625994
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020;26:3589–96.
doi: 10.1158/1078-0432.CCR-19-3815
pubmed: 32198151
pmcid: 8588795
Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5:4054–8.
doi: 10.1182/bloodadvances.2021005083
pubmed: 34478505
pmcid: 8945613
Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132:892–902.
doi: 10.1182/blood-2018-01-826008
pubmed: 29997221
Hoffmann A, Dietrich S, Hain S, Rieger M, Hegenbart U, Sellner L, et al. Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. Haematologica. 2019;104:e304–6.
doi: 10.3324/haematol.2018.209486
pubmed: 30630979
pmcid: 6601102
Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, et al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020;4:3977–89.
doi: 10.1182/bloodadvances.2020001956
pubmed: 32841336
pmcid: 7448605
Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020;4:4113–23.
doi: 10.1182/bloodadvances.2020002184
pubmed: 32882002
pmcid: 7479951
Tournilhac O, Dreger P Chronic Lymphocytic Leukaemia. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook. Cham (CH): Springer; 2022. http://www.ncbi.nlm.nih.gov/books/NBK584167/ .
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602:503–9.
doi: 10.1038/s41586-021-04390-6
pubmed: 35110735
pmcid: 9166916
Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, et al. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Front Immunol. 2020;11:594556.
doi: 10.3389/fimmu.2020.594556
pubmed: 33312177
pmcid: 7708380
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892–901.
doi: 10.1016/S0140-6736(21)00224-5
pubmed: 33676628
Mato A. Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. In ASH; 2021. https://ash.confex.com/ash/2021/webprogram/Paper147599.html .
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors. N Engl J Med. 2022;386:735–43.
doi: 10.1056/NEJMoa2114110
pubmed: 35196427
pmcid: 9074143